Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.60 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12400239 | 0.92 | SLC7A5 (0.68) | SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1 | |
| SCHEMBL7031797 | 0.91 | SLC7A5 (0.52) | SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1 | |
| SCHEMBL4394735 | 0.87 | SLC7A5 (0.62) | SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1 | |
| SCHEMBL8427611 | 0.86 | CYP4F2 (0.69) | SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1 | |
| SCHEMBL14704371 | 0.86 | SLC7A5 (0.57) | SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1 | |
| SCHEMBL12508635 | 0.85 | SLC7A5 (0.60) | SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1 | |
| SCHEMBL1560308 | 0.85 | SLC7A5 (0.65) | SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1 | |
| SCHEMBL694460 | 0.85 | SLC7A5 (0.65) | SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1 | |
| SCHEMBL13460869 | 0.84 | SLC7A5 (0.49) | SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1 | |
| SCHEMBL8655484 | 0.84 | SLC7A5 (0.59) | SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3456719-A1 | COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10087172-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-10-02 | — | — | US | disclosed |
| EP-2922850-B1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-2922850-B1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20150291576-A1 | COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-15 | — | — | US | disclosed |
| US-20150291576-A1 | COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-15 | — | — | US | disclosed |
| US-20150291576-A1 | COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-15 | — | — | US | disclosed |
| WO-2014079150-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| WO-2012097427-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC BIOSCIENCES INC. (CA) | 2012-07-26 | — | — | WO | disclosed |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2012-04-12 | — | — | US | disclosed |
| WO-2010127440-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC BIOSCIENCES INC. (CA) | 2010-11-11 | — | — | WO | disclosed |
| US-7449576-B1 | potent antagonists of the CCR1 receptor; inflammation; (5-Chloro-2-piperazin-1-yl-phenyl)-phenyl-methanone | CHEMOCENTRYX, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291576-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | SLC7A5 393/4885CYP4F2 854/4885CYP4A11 1548/4885 |
| US-10087172-B2 | Compounds and their methods of use | GLS, GLS2, GLUL | SLC7A5 393/4885CYP4F2 854/4885CYP4A11 1548/4885 |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | TYR, PAH, REN | SLC7A5 453/4885CYP4F2 74/4885CYP4A11 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.